Novavax, Inc.

General ticker "NVAX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.6B (TTM average)

Novavax, Inc. follows the US Stock Market performance with the rate: 0.7%.

Estimated limits based on current volatility of 3.1%: low 5.96$, high 6.34$

Factors to consider:

  • North America accounted for 9.5% of revenue in the fiscal year ended 2024-12-31
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [5.21$, 13.58$]
  • 2025-12-31 to 2026-12-31 estimated range: [2.87$, 8.13$]

Financial Metrics affecting the NVAX estimates:

  • Negative: Non-GAAP EPS, $ of -1.33 <= 0.04
  • Negative: Operating cash flow per share per price, % of -6.16 <= 1.79
  • Negative: negative Operating income
  • Negative: Shareholder equity ratio, % of -39.98 <= 22.52
  • Negative: negative Net income
  • Positive: -3.20 < Investing cash flow per share, $ of -1.34
  • Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82

Similar symbols

Short-term NVAX quotes

2025-03-112025-03-122025-03-132025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-2255.566.577.588.5
Price $

Long-term NVAX plot with estimates

5101520Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−1−0.500.51
NVAXS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $1,598.95MM $556.38MM $682.16MM
Operating Expenses $2,243.69MM $1,122.89MM $931.09MM
Operating Income $-644.74MM $-566.51MM $-248.93MM
Non-Operating Income $-8.91MM $23.48MM $72.32MM
Interest Expense $19.88MM $14.42MM $20.07MM
R&D Expense $1,235.28MM $737.50MM $391.17MM
Income(Loss) $-653.65MM $-543.03MM $-176.62MM
Taxes $4.29MM $2.03MM $10.88MM
Profit(Loss)* $-657.94MM $-545.06MM $-187.50MM
Stockholders Equity $-634.08MM $-716.93MM $-623.84MM
Inventory $36.68MM $41.70MM $8.75MM
Assets $2,258.68MM $1,797.49MM $1,560.42MM
Operating Cash Flow $-415.94MM $-713.97MM $-87.26MM
Capital expenditure $92.98MM $58.81MM $13.06MM
Investing Cash Flow $-92.98MM $-58.81MM $-204.04MM
Financing Cash Flow $324.99MM $4.47MM $260.58MM
Earnings Per Share** $-8.42 $-5.41 $-1.23

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.